Johnson & Johnson
🇺🇸United States
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1886-01-01
- Employees
- 131.9K
- Market Cap
- $392.2B
- Website
- http://www.jnj.com
- Introduction
Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in the interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.
How HIV research has reshaped modern medicine
HIV research has transformed the infection from a death sentence into a manageable chronic condition, affecting 1.2 million people in the U.S. and nearly 40 million worldwide. Key advancements include antiretroviral therapy (ART) and pre-exposure prophylaxis (PrEP), with ongoing efforts focused on developing a vaccine. Insights from HIV research have also significantly influenced the development of COVID-19 vaccines and treatments for other diseases.
Gene Switch Market Impacts on Medicine and Biotechnology Sector
The Gene Switch Market is projected to grow from USD 0.78 Bn in 2024 to USD 1.78 Bn by 2031, with a CAGR of 11.6%. CoherentMI's report provides a comprehensive analysis of market trends, competitive landscape, and key players like Novartis, Pfizer, and Gilead Sciences.
FDA's Psychedelic Reckoning
Psychedelic drug developers face setbacks but see potential in Johnson & Johnson's Spravato success. Cybin, a Toronto-based company, benefits from FDA insights gained from Lykos and Compass's issues, advancing its Phase 3 trial for deuterated psilocin (CYB003) for major depressive disorder. Cybin emphasizes FDA-desired trial details and patient safety measures, leveraging breakthrough therapy designation for real dialogue with the agency. The expanding infrastructure for Spravato administration supports future psychedelic drug rollouts.
Allergy Relieving Eye Drops Market Global Forecast Report
The Allergy Relieving Eye Drops Market is projected to grow from USD 1.51 billion in 2023 to USD 2.37 billion by 2032, driven by rising allergy prevalence, demand for non-invasive solutions, and advancements in eye drop formulations. Key markets include Canada, France, India, and UAE, with major companies like AbbVie, Johnson & Johnson, and Pfizer leading the industry.
clinical trial genAI-powered control tower, Vivo, wins 1st place in the CNS ...
Vivo, developed by OmniScience, won the CNS Summit Innovation Showcase for its ability to streamline clinical trial data accessibility and support actionable insights. The platform's genAI capabilities enable teams to make informed decisions, reducing trial timelines and increasing success rates.
AstraZeneca claims phase 3 success with combination therapy for prostate cancer
AstraZeneca's CAPItello-281 phase 3 trial showed significant improvements in radiographic progression-free survival (rPFS) with Truqap (capivasertib) combined with Zytiga (abiraterone) and ADT in PTEN-deficient de novo metastatic hormone-sensitive prostate cancer patients, compared to Zytiga and ADT alone. The trial, involving over 1,000 patients, marks the first AKT inhibitor combination to demonstrate benefit in this specific form of prostate cancer, with ongoing assessment for overall survival.
Johnson & Johnson Seeks FDA Approval For Subcutaneous Induction Regimen Of TREMFYA
Johnson & Johnson submitted an sBLA to the FDA for TREMFYA's SC induction regimen in UC, supported by Phase 3 ASTRO study data. The study met primary and secondary endpoints, showing clinical remission and endoscopic improvement. TREMFYA, an IL-23 inhibitor, aims to simplify treatment for UC and CD patients.
IMD Future Readiness Indicator - Pharmaceutical 2024
Top global pharma companies excel in R&D, pipeline management, and capital allocation, leveraging AI, personalized medicine, and supply chain resilience. Leaders like Roche and Novo Nordisk face challenges in valuation, access vs. profitability, and innovation pipeline management, emphasizing the need for balanced strategies and portfolio diversification.
As of 1:30 p.m. on the 26th, the top 1% of stock investment returns were confirmed to have net purch..
Top 1% investors net purchased Yuhan, Alteogen, and HD Hyundai Heavy Industries as of 1:30 p.m. on the 26th, while net selling Doosan, Korea Electric Power Corp., and Daedong. Yuhan's stock price fell 3.89%, seen as a buying opportunity, and Alteogen's stock price dropped 33%, also attracting buyers.
New data could help Merck expand use of cardiovascular drug
Merck's Winrevair, added to background therapy, helped severe lung hypertension patients stay alive and avoid invasive care longer. The ZENITH trial's interim data showed Winrevair outperformed placebo, potentially expanding its use and peak annual earnings to $5 billion. Winrevair treats pulmonary arterial hypertension, improving walking speed and delaying complications, with the ZENITH study focusing on severe cases.
© Copyright 2024. All Rights Reserved by MedPath